Cytokines, chemokines and other biomolecular markers in sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 22, Issue SUPPL. 1, 2005, Pages

  Gurrieri, Carmela ^a   Bortoli, Michela ^a   Brunetta, Enrico ^a   Piazza, Francesco ^a   Agostini, Carlo ^a,b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Alveolitis; Chemokines; Granuloma; Sarcoidosis

Indexed keywords

BIOCHEMICAL MARKER; CHEMOKINE; CYTOKINE; MOLECULAR MARKER;

CELL INTERACTION; CONFERENCE PAPER; DISEASE ACTIVITY; GRANULOMATOSIS; GRANULOMATOUS INFLAMMATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LUNG ALVEOLITIS; LUNG DISEASE; MOLECULAR MECHANICS; PATHOGENESIS; PRIORITY JOURNAL; SARCOIDOSIS; TH1 CELL; TH2 CELL;

BIOLOGICAL MARKERS; CHEMOKINES; CHRONIC DISEASE; CYTOKINES; DISEASE PROGRESSION; FEMALE; GRANULOMA; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 31544455867     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Semenzato G, Adami F, Maschio N, Agostini C: Immune mechanisms in interstitial lung diseases. Allergy 2000; 55: 1103-20.
2. Semenzato G, Bortolin M, Facco M, Tassinari C, Sancetta R, Agostini C: Lung lymphocytes: origin, biological functions, and laboratory techniques for their study in immune-mediated pulmonary disorders. Crit Rev Clin Lab Sci 1996; 33: 423-55.
3. Semenzato G, Pezzutto A, Agostini C, Gasparotto G, Cipriani A: Immunoregulation in sarcoidosis. Clin Immunol Immunopathol 1981; 19: 416-27.
4. Meloni F, Caporali R, Marone Bianco A, et al: BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 111-18.
5. Agostini C, Trentin L, Perin A, et al: Regulation of alveolar macrophage-T cell interactions during Th1-type sarcoid inflammatory process. Am J Physiol 1999; 277: L240-50.
6. Xaus J, Besalduch N, Comalada M, et al: High expression of p21 Waf1 in sarcoid granulomas: a putative role for long-lasting inflammation. J Leukoc Biol 2003; 74: 295-301.
7. Hunninghake GW, Bedell GN, Zavala DC, Monick M, Brady M: Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. Am Rev Respir Dis 1983; 128: 634-8.
8. Pinkston P, Bitterman PB, Crystal RG: Spontaneous release of interleukin-2 by lung T lymphocytes in active pulmonary sarcoidosis. N Engl J Med 1983; 308: 793-800.
9. Muller-Quernheim J, Pfeifer S, Kienast K, Zissel G: Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis. Lung 1996; 174: 243-53.
10. Rutherford RM, Staedtler F, Kehren J, et al: Functional genomics and prognosis in sarcoidosis - the critical role of antigen presentation. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 10-18.
11. Shigehara K, Shijubo N, Ohmichi M, et al: Enhanced mRNA expression of Th1 cytokines and IL-12 in active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 151-7.
12. Minshall EM, Tsicopoulos A, Yasruel Z, et al: Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur Respir J 1997; 10: 2034-9.
13. Moller DR, Forman JD, Liu MC, et al: Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-60.
14. Taha RA, Minshall EM, Olivenstein R, et al: Increased expression of IL-12 receptor mRNA in active pulmonary tuberculosis and sarcoidosis. Am J Respir Crit Care Med 1999; 160: 1119-23.
15. Rogge L, Papi A, Presky DH, et al: Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol 1999; 162: 3926-32.
16. Larousserie F, Pflanz S, Coulomb-L'Hermine A, Brousse N, Kastelein R, Devergne O: Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004; 202: 164-71.
17. Greene CM, Meachery G, Taggart CC, et al: Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 2000; 165: 4718-24.
18. Fukami T, Miyazaki E, Matsumoto T, Kumamoto T, Tsuda T: Elevated expression of interleukin-18 in the granulomatous lesions of muscular sarcoidosis. Clin Immunol 2001; 101: 12-20.
19. Shigehara K, Shijubo N, Ohmichi M, et al: IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001; 166: 642-9.
20. Shigehara K, Shijubo N, Ohmichi M, et al: Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 162: 1979-82.
21. Chen B, Tong Z, Nakamura S, Costabel U, Guzman J: Production of IL-12, IL-18 and TNF-alpha by alveolar macrophages in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 199-203.
22. Antoniou KM, Alexandrakis MG, Sfiridaki K, et al: Th1 cytokine pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 105-10.
23. Drent M, van den Berg R, Haenen GR, van den Berg H, Wouters EF, Bast A: NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 50-6.
24. Abdallah A, Sato H, Grutters JC, et al: Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun 2003; 4: 450-4.
25. Kanazawa N, Okafuji I, Kambe N, et al: Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-(kappa)B activation: common genetic etiology with Blau syndrome. Blood 2004; 105: 1195-7.
26. Culver DA, Barna BP, Raychaudhuri B, et al: Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 2004; 30: 1-5.
27. Agostini C, Trentin L, Facco M, et al: Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996; 157: 910-18.
28. Zissel G, Baumer I, Schlaak M, Muller-Quernheim J: In vitro release of interleukin-15 by broncho-alveolar lavage cells and peripheral blood mononuclear cells from patients with different lung diseases. Eur Cytokine Netw 2000; 11: 105-12.
29. Gibejova A, Mrazek F, Subrtova D, et al: Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis. Am J Respir Crit Care Med 2003; 167: 1695-703.
30. Farber JM: Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61: 246-57.
31. Agostini C, Adami F, Semenzato G: New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 2000; 12: 71-6.
32. Agostini C: Cytokine and chemokine blockade as immunointervention strategy for the treatment of diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 18-22.
33. Lipscomb MF, Bice DE, Lyons CR, Schuyler MR, Wilkes D: The regulation of pulmonary immunity. Adv Immunol 1995; 59: 369-455.
34. Huang H, Meyer KC, Kubai L, Auerbach R: An immune model of beryllium-induced pulmonary granulomata in mice. Histopathology, immune reactivity, and flow-cytometric analysis of bronchoalveolar lavage-derived cells. Lab Invest 1992; 67: 138-46.
35. Gudmundsson G, Hunninghake GW: Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997; 99: 2386-90.
36. Takahashi R, Shijubo N, Shigehara K, Hiraga Y, Abe S, Sato N: T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 204-11.
37. Agostini C: Tailoring immunosuppressive therapy in interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 3-9.